US Business U.S. formulation business reported revenue of `2,226.8 Crs. witnessing a growth of 6.1% YoY and 17.8% on a sequential basis. US business reported healthy growth inspite of high base due to one-off opportunity in Q2FY18. The launch of Ertapenem and shortage of Valsartan helped to report improved volumes in the US. During the quarter, Aurobindo received final approvals for 13 ANDAs including one injectable and filed 25 ANDAs including 8 ANDAs for injectable products. The management has maintained their growth guidance for the injectable business of ~30% growth for FY19and...